Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Mar 6.
doi: 10.1007/s10620-026-09773-1. Online ahead of print.

Severe Influenza-Related Outcomes in Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy: A Propensity-Matched Cohort Analysis

Mohamed H Eldesouki  1 , Ahmed Ibrahim  2 , Omar Alkasabrah  3 , Mohammed Y Youssef  4 , Eslam Mohamed  5 , Saqr Alsakarneh  6 , Francis A Farraye  7 , Jana G Hashash  7
Affiliations

Severe Influenza-Related Outcomes in Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy: A Propensity-Matched Cohort Analysis

Mohamed H Eldesouki et al. Dig Dis Sci. .

Abstract

Background: Patients with active inflammatory bowel disease (IBD) often require immunosuppressive therapy to achieve and maintain remission; however, the impact of these medications on influenza risk and the severity of influenza-related complications remains inadequately characterized.

Methods: Using the TriNetX U.S. Analytics Network, adults (≥ 18 years) with Crohn's disease or ulcerative colitis during the 2022-2023 influenza season were identified. Patients were stratified by disease activity into two cohorts: (1) active IBD, defined by elevated inflammatory markers, initiation of corticosteroids or a new biologic or small-molecule agent, or documented IBD-related symptoms or complications within the prior six months; and (2) inactive IBD, defined by the absence of these features and no recent immunosuppressive therapy. Propensity score matching (1:1) was used to balance baseline characteristics, and Cox proportional hazards models were applied to estimate hazard ratios for influenza-related outcomes.

Results: After propensity score matching, each group had 22,784 patients. The incidence of influenza diagnosis was significantly higher in the active IBD group (HR 1.41; 95% CI 1.30-1.52). Hospitalization rates were also increased (HR 2.05; 95% CI 1.89-2.23), as were influenza-related complications (HR 1.36; 95% CI 1.23-1.51). ICU admissions (HR 1.51; 95% CI 1.33-1.72) and mechanical ventilation (HR 1.68; 95% CI 1.32-2.13) were both more frequent in the active IBD group. Use of antiviral medications was higher among patients with active IBD (HR 1.60; 95% CI 1.22-2.10), and overall mortality was modestly increased (HR 1.17; 95% CI 1.02-1.35). Subgroup analysis revealed the highest risk among patients on corticosteroids, followed by JAK inhibitors and anti-IL-23 agents.

Conclusion: Patients with active IBD had more severe influenza-related outcomes compared with those with inactive IBD. Improving vaccine uptake and prompt evaluation of upper respiratory symptoms during influenza seasons are key to reducing influenza-related risks in immunosuppressed patients with IBD.

Keywords: Biologic agents; Immunosuppressive therapy; Inflammatory bowel disease; Influenza.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The contributing authors have no financial, professional, personal, or other conflicts of interest to declare. Disclosures: Dr. Farraye has served as a Consultant for Astellas, Avalo Therapeutics, Bausch, BMS, Braintree Labs, Fresenius Kabi, GI Reviewers, IBD Educational Group, Iterative Health, Janssen, Pharmacosmos, Pfizer, Sandoz Immunology, Viatris.He sits on a DSMB for Eli Lilly and Moon Lake.

References

    1. Tyrrell CS, Allen JLY, Gkrania-Klotsas E. Influenza: epidemiology and hospital management. Medicine (Abingdon). 2021;49:797–804. https://doi.org/10.1016/j.mpmed.2021.09.015 . - DOI - PubMed - PMC
    1. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121:258–264. https://doi.org/10.1016/j.amjmed.2007.10.040 . - DOI - PubMed - PMC
    1. Gordon A, Reingold A. The burden of influenza: a complex problem. Curr Epidemiol Rep. 2018;5:1–9. https://doi.org/10.1007/s40471-018-0136-1 . - DOI - PubMed - PMC
    1. O’Halloran AC, Millman AJ, Holstein R et al. The burden of all-cause mortality following influenza-associated hospitalizations: influenza hospitalization surveillance network, 2010–2019. Clin Infect Dis. 2025;80:e43–e45. https://doi.org/10.1093/cid/ciae547 . - DOI - PubMed - PMC
    1. Beaugerie L, Kirchgesner J. Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory Bowel diseases. Clin Gastroenterol Hepatol. 2019;17:370–379. https://doi.org/10.1016/j.cgh.2018.07.013 . - DOI - PubMed

LinkOut - more resources